So first the trial and Im just going to cut and paste from Lillys pressor on this part as to what the trial actually is: TRIUMPH-4 (NCT05869903) is a Phase 3, 68-week, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of retatrutide with placebo in adults with obesity or overweight and knee osteoarthritis
Four PDK isozymes have been identified in humans: PDK1, PDK2, PDK3, and PDK4, each of which is encoded by a distinct gene
Neither has enough direct comparative clinical research to be declared universally superior
The FLOW study highlights the risks of CKD progression, cardiovascular disease and death in those with type 2 diabetes and CKD, and the significant benefits of the pillars of treatment: ACE inhibitors/ARBs, SGLT2 inhibitors, finerenone and, now, semaglutide